AxoGen, Inc. (AXGN)
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
$47.27+1.24%
Close 2026-09-09 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-09-09
Warn: Primary pillar under pressure — Maintain gross margin between 74% and 76% in 2026: FY26 GM guidance 73.0% vs 74-76% target; Q2 actual 72.7%.
AxoGen aims for 20% revenue growth in 2026, targeting $270 million. Gross margin should stay between 74% and 76%. Cash from operations rose to $1.57 million in Q1. The company is growing sales and keeping profit margins wide.
AxoGen is still loss-making and free cash flow positive is uncertain. High valuation at 117 PE risks a price drop. FDA litigation could hurt growth and profits.
The price is about 11% above our fair value near $40. Analysts expect 22% revenue growth, which matches management's 20% target.
Breaks if: free cash flow remains negative through FY26
Breaks if: gross margin falls below 70% in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
AXGN represents a speculative growth investment. The company is focused on achieving significant revenue growth and positive cash flow, but it is currently loss-making and faces moderate risk in a high-miss-rate industry.
The market appears to have priced in a stretched valuation, reflecting expectations of future growth. There is an expectations gap of 0.22, indicating that investors may anticipate some improvement in performance.
Management is on track to achieve at least 24% revenue growth in 2026, although maintaining gross margins has been mixed. The company is making progress toward positive free cash flow, but the final outcome remains uncertain.
The thesis hinges on management's ability to meet growth targets and maintain margins. Additionally, the performance of sector bellwethers and overall economic conditions will influence AXGN's trajectory.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings report showed a beat, which supports the thesis. There are no new threats identified at this time.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Management aims to maintain gross margin in the range of 74% to 76% for 2026.
Breaks if: YoY revenue growth falls below 15% in FY26
AXGN's outlook is supported by stable management and positive sector trends, but it must navigate risks related to guidance and economic conditions. Not investment advice.